홈 > 연구소 > 논문 / 학술활동
연구소
마마파파&베이비의 핵심인 베이비 드림 난임 연구소는
그간의 연구학술 성과에 안주하지 않고,
늘 한계를 뛰어넘기 위해 노력합니다.
2016년 미국불임학회(ASRM) P-595 IS IMMUNOTHERAPY USEFUL IN RECURRENT IMPLANTATION FAILURE PATIENTS; ESPECIALLY WITH HIGH NATURAL KILLER CELL? (반복착상 실패 환자 에서 면역치료요법이 유용할 것인가; 특히 높은 자연살해세포를 가진 환자에서?)
H. Sun,1 K. Lee,1 I. Park,1 S. Kim,1 H. Chi,1 J. Kim,1 J. Cho2; 1Mamapapa & Baby OB&GY Clinic, Ulsan,
Korea, Republic of, 2Ellemedi Women's Hospital, Changwon, Korea, Republic of
IVIG is an established treatment in several autoimmune and inflammatory diseases and has been tested in several RCTs in recurrent miscarriage (RM) patients. Although clinically different disorders, RIF has been suggested to share many characteristics with early RM. Immunological parameters that seem associated with both RIF and RM are increased numbers of peripheral blood natural killer cells. There were several reviews of IVIG efficacy in RM patients with high NK cell, but there were few studies in RIF patients.
This retrospective study included 295 cases third IVF cycles between January 2011 and October 2015.
In 295 cases with previous two IVF-ET failure cycles, 81 women had blood tests for NK cell assay and were treated with intravenous immunoglobulin (IVIG) 400mg/kg on ET day and repeated if pregnancy test was positive (IVIG group). We divided IVIG group into two groups with high NK cell (≥12%) group and normal NK cell (<12%) group.
Total pregnancy rate of third IVF cycle was 29.8% (88/295). In 81 cases, patients had blood tests for NK cell assay and were treated with intravenous immunoglobulin (IVIG group). Among IVIG group, patients with high NK cell (≥12%) were 58.0% (47/81) and normal NK cell (<12%) were 42.0% (34/81). Pregnancy rate was significantly higher in high NK cell group than in normal NK cell group [55.3% (26/47) vs. 26.5% (9/34), p=0.018]. And pregnancy rate was significantly higher in IVIG group with high NK cell than in no IVIG treatment patients [55.3% (26/47) vs. 24.8% (53/214), p=0.015]. But pregnancy rate showed no significant difference between normal NK cell IVIG group and no IVIG treatment patients [26.5% (9/34) vs. 24.8% (53/214), p=0.926]. IVIG treated patients with high NK cell showed improved IVF outcome than patients without IVIG treatment. But IVIG treatment with normal NK cell did not affect IVF outcome.
IVIG treatment enhances pregnancy rate in RIF patients with high NK cell, but do not affect IVF outcome in patients with normal NK cell. Our results showed that more than half of RIF patients had increased NK cell level. In these patients, IVIG treatment was resulted in increasing more than twice pregnancy rate. Therefore if clinicians encounter repeated IVF failure, we recommend proper evaluation and treatment about RIF causes including NK cell.